Table 3 Comparison between the studied patients with normal and abnormal cardiac MRI

Demographic and clinical characteristics

Age (years), M ± SD

26.0 ± 2.65

33.56 ± 9.22

.084

Sex

 Male, n (%)

2 (40)

19 (76)

.109

 Female, n (%)

3 (60)

6 (24)

Behçet's disease duration (years), median (min–max)

2 (2–3)

3 (1–7)

.176

Height (cm), M ± SD

171.6 ± 4.77

170.92 ± 5.71

.723

Weight (kg), M ± SD

74 ± 8.22

75.64 ± 9.54

.723

BMI (kg/m²), M ± SD

25.08 ± 1.86

25.96 ± 3.6

.60

Heart rate (bpm), M ± SD

88 ± 4.47

89.9 ± 8.23

.641

SBP (mmHg), M ± SD

124 ± 5.47

128.2 ± 6.59

.19

DBP (mmHg), M ± SD

70 ± 7.07

80 ± 9.13

.806

Behcet disease activity index score, M ± SD

 ≤ 4, n (%)

1(20)

14(56)

.33

 > 4, n (%)

4(80)

11(44)

Cumulative manifestations of Behcet disease

 Orogenital Ulcers

5(100)

25(100)

1

 Uveitis

4(80.0)

19(76.0)

1

 Cutaneous manifestations

1(20.0)

10(40.0)

.63

 Musculoskeletal manifestations

2 (40)

8 (32)

1

 Gastrointestinal tract manifestations

1 (20)

1(4)

1

 Deep venous thrombosis

1(20)

3 (12)

.53

Laboratory characteristics

Complete blood count

 Hb (g/dL), M ± SD

11.90 ± 0.74

11.82 ± 1.07

.88

 WBCs (10³ /mm³), M ± SD

4.26 ± 0.78

4.71 ± 0.71

.21

 PLT (10³ /mm³), M ± SD

225.0 ± 32.02

222.36 ± 57.48

.92

Serum creatinine (mg/dL), M ± SD

0.86 ± 0.09

0.916 ± 0.11

.312

Erythrocyte sedimentation rate (mm/hr), M ± SD

33.0 ± 12.04

33.0 ± 12.04

.58

Positive C-reactive protein, n (%)

2(40)

12(48)

1

Medications used for treatment, n (%)

 Colchicine

5 (100)

25 (100)

1

 Steroids

5 (100)

25 (100)

1

 Azathioprine

4 (80)

10 (40)

.157

 Cyclosporine

1 (20)

11 (44)

.62

 Anticoagulants

1 (20)

4 (16)

1

 Biological agents

1 (20)

9 (36)

.64